Literature DB >> 27909220

Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.

Paola Tacchetti1, Annalisa Pezzi1, Elena Zamagni1, Lucia Pantani1, Serena Rocchi1, Beatrice Anna Zannetti1, Katia Mancuso1, Ilaria Rizzello1, Michele Cavo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27909220      PMCID： PMC5394964          DOI： 10.3324/haematol.2016.154070

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Authors:  A R Bradwell; H D Carr-Smith; G P Mead; L X Tang; P J Showell; M T Drayson; R Drew
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

2.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

3.  Serum test for assessment of patients with Bence Jones myeloma.

Authors:  Arthur R Bradwell; Hugh D Carr-Smith; Graham P Mead; Timothy C Harvey; Mark T Drayson
Journal:  Lancet       Date:  2003-02-08       Impact factor: 79.321

4.  Serum free light chains for monitoring multiple myeloma.

Authors:  G P Mead; H D Carr-Smith; M T Drayson; G J Morgan; J A Child; A R Bradwell
Journal:  Br J Haematol       Date:  2004-08       Impact factor: 6.998

5.  Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.

Authors:  C L H Snozek; J A Katzmann; R A Kyle; A Dispenzieri; D R Larson; T M Therneau; L J Melton; S Kumar; P R Greipp; R J Clark; S V Rajkumar
Journal:  Leukemia       Date:  2008-07-03       Impact factor: 11.528

6.  Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

Authors:  Thomas Dejoie; Michel Attal; Philippe Moreau; Jean-Luc Harousseau; Herve Avet-Loiseau
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

7.  Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.

Authors:  Paola Tacchetti; Michele Cavo; Serena Rocchi; Annalisa Pezzi; Lucia Pantani; Annamaria Brioli; Nicoletta Testoni; Carolina Terragna; Beatrice Anna Zannetti; Katia Mancuso; Giulia Marzocchi; Enrica Borsi; Marina Martello; Ilaria Rizzello; Elena Zamagni
Journal:  Leuk Lymphoma       Date:  2016-01-14

Review 8.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

9.  Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.

Authors:  J T Larsen; S K Kumar; A Dispenzieri; R A Kyle; J A Katzmann; S V Rajkumar
Journal:  Leukemia       Date:  2012-10-16       Impact factor: 11.528

10.  Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Authors:  Annamaria Brioli; Hannah Giles; Charlotte Pawlyn; John P Campbell; Martin F Kaiser; Lorenzo Melchor; Graham H Jackson; Walter M Gregory; Roger G Owen; J Anthony Child; Faith E Davies; Michele Cavo; Mark T Drayson; Gareth J Morgan
Journal:  Blood       Date:  2014-04-14       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.